Tallimustine in Advanced Colorectal Cancer
Author Information
Author(s): CJA Punt, Y Humblet, E Roca, LY Dirix, R Wainstein, A Polli, I Corradino
Primary Institution: University Hospital Nijmegen
Hypothesis
Does tallimustine have anti-tumour activity in previously untreated patients with advanced colorectal cancer?
Conclusion
Tallimustine showed no anti-tumour activity in patients with advanced colorectal cancer despite its unique mechanism of action.
Supporting Evidence
- 17 patients were enrolled in the study.
- 14 evaluable patients showed no responses.
- Toxicity mainly consisted of neutropenia.
Takeaway
Tallimustine is a new cancer drug, but it didn't help patients with advanced colorectal cancer in this study.
Methodology
Phase II study with 17 previously untreated patients receiving tallimustine via i.v. bolus infusions every 4 weeks.
Limitations
No responses were documented in 14 evaluable patients, indicating a lack of efficacy.
Participant Demographics
13 males and 4 females, median age 58 years.
Statistical Information
Confidence Interval
0-23%
Want to read the original?
Access the complete publication on the publisher's website